We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cell Cannibalism May Lead to Cancer Control Therapy

By LabMedica International staff writers
Posted on 25 Jul 2017
Print article
Image: A cell in the process of dividing (center) that is being engulfed by cells on either side. DNA is shown in blue and a protein responsible for attachment between cells is shown in green (Photo courtesy of Dr. Jo Durgan, Babraham Institute).
Image: A cell in the process of dividing (center) that is being engulfed by cells on either side. DNA is shown in blue and a protein responsible for attachment between cells is shown in green (Photo courtesy of Dr. Jo Durgan, Babraham Institute).
An unexpected link between cell division and cell cannibalism (entosis), which is relevant to both cancer and chemotherapy, was described in a recent paper.

Entosis is a form of epithelial cell cannibalism that is prevalent in human cancer, typically triggered by loss of matrix adhesion. In the laboratory, entosis has only been seen in cells that are detached from their surroundings. Cells in the body are typically surrounded and supported by a mesh of proteins called the extracellular matrix. However, within a tumor, cancer cells can often begin to grow without being attached to the matrix, which means that entosis can occur. A protein called Cdc42 (Cell division control protein 42 homolog) plays a part in how cells attach to each other and to the extracellular matrix, but the role of Cdc42 in controlling entosis had not been previously explored.

Investigators at the Babraham Institute (Cambridge, United Kingdom) initially set out to ask whether Cdc42 was involved in the established process of cell cannibalism, as seen in detached cells. However, the experiments showed that removing Cdc42 from human cells grown in the laboratory had little effect on this method of entosis.

On the other hand, the loss of Cdc42 did enable a different form of entosis in cells that remained attached to the extracellular matrix, which had not been seen before. This new process of entosis was linked to cell division (mitosis), with cells that were dividing or that had recently divided being consumed by neighbors.

During cell division a group of proteins - including RhoA and myosin - cause cells to become rounder and stiffer, allowing the dividing cells to force their way inside other cells. This is the key first stage of entosis. Since cancer cells divide often, this form of cell cannibalism may lead to the cancer cells being destroyed by their healthy neighbors, in a form of “assisted suicide”. This form of entosis is more commonly seen in cancers where the cells divide frequently, and some chemotherapy drugs that interfere with cell division also increase the rate of cell cannibalism.

Senior author Dr. Oliver Florey, a researcher at the Babraham Institute, said, "Entosis is a fascinating process that may play a role in normal physiology, as well as cancer. By studying entosis, we hope to gain insights into fundamental cell biology, as well as to explore intriguing new avenues for cancer research. After 100 years of observing "cell-in-cell" structures, there is now an exciting push towards discoveries in both cell and cancer biology."

The mitosis entosis study was published in the July 11, 2017, online edition of the journal eLife.

Related Links:
Babraham Institute

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.